Averting a malaria disaster

Lancet

Volumn 353, Issue 9168, 1999, Pages 1965-1967

  White, N J ^a,b   Nosten, F ^a   Looareesuwan, S ^b   Watkins, W M ^j   Marsh, K ^j   Snow, R W ^j   Kokwaro, G ^j   Ouma, J ^j   Hien, T T ^c   Molyneux, M E ^d   Taylor, T E ^j   Newbold, C I ^e   Ruebush II, T K ^f   Danis, M ^g   Greenwood, B M ^h   Anderson, R M ^e   Olliaro, P ⁱ  

^a MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHO QUAN HOSPITAL   (Viet Nam)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; FANSIDAR; HALOFANTRINE; MEFLOQUINE;

BRAIN STEM INJURY; CLINICAL PRACTICE; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG COST; DRUG ELIMINATION; DRUG MECHANISM; DRUG RESISTANCE; GENE MUTATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALARIA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033526595     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07367-X     Document Type: Note

References (13)

1. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993; 167: 932-37.
2. Ronn A, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 1996; 90: 179-81.
3. Marsh K. Malaria disaster in Africa. Lancet 1998; 352: 924-25.
4. Harlem Brundtland G. Speech to the fifty-first World Health Assembly. Geneva: 13 May, 1998.
5. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in-vivo. Antimicrob Agents Chemother 1997; 41: 1413-22.
6. Price RN, Nosten F, Luxemburger C, et al. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91: 574-77.
7. Van Vugt M, Brockman A, Gemperli B, et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 1998; 42: 135-39.
8. White NJ. Preventing antimalarial drug resistance through combinations. Drug Resis Update 1998; 1: 3-9.
9. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347: 1654-58.
10. Handunnetti SM, Gunewardena DM, Pathirana PPSL, Ekanayake K, Weerasinghe S, Mendis KN. Features of recrudescent chloroquine-resistant Plasmodium falciparum infections confer a survival advantage on parasites and have implications for disease control. Trans R Soc Trop Med Hyg 1996; 90: 563-67.
11. Watkins WM, Msobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993; 87: 75-78.
12. Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxocity of arteether and artemether. Am J Trop Med Hyg 1994; 51: 251-59.
13. Snow RW, Peshu N, Forster D, Mwenesi H, Marsh K. The role of shops in the treatment and prevention of childhood malaria on the coast of Kenya. Trans R Soc Trop Med Hyg 1992; 86: 237-39.